RE:RE:RE:M Partners Top PickWas hoping for a breakeven but obviously not the case.
Pandemic his a big and real factor when you look at was is happening in the medical environnement.
Develolpping and marketing their product in the US is excellent.
But the big plus factor woul be a factor i a buyout ...
So I stay in and ready to average a bit lower.
uote=bossu]Financial report :
Opsens to release Q1 2022 financial results Jan. 13 Great potential and a break even and
- Cash and cash equivalents at $38.6-million as of Aug. 31, 2021, an increase of $27.7-million versus last year period ended Aug. 31, 2020.
A revenu increase for the Q1 would be a good start,
- Record total revenue of $34.5-million in FY 2021 compared with $29.5-million in FY 2020, a 17-per-cent increase;
- Record sales of coronary artery disease products at $22.9-million in FY 2021, compared with $18.7-million in FY 2020, a 22-per-cent increase;
Last year was a $ 1 ,5 M loss. compare to a loss of $ 2,5 M in the FY 2020.
So sales are growing and loss heading down
The storey is just beginning but a share drop financial report is not a good sign.
[/quote]